WHOCC
Postal address:
Norwegian Institute of Public Health
WHO Collaborating Centre for Drug Statistics Methodology
Postboks 222 Skøyen
0213 Oslo
Norway

Visiting/delivery address:
Myrens verksted 6H
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New search    Hide text from Guidelines

G GENITO URINARY SYSTEM AND SEX HORMONES
G03 SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM

Other hormones, see H - Systemic hormonal preparations, excl. sex hormones and insulins.
Sex hormones used only in the treatment of neoplastic diseases (often selected strengths) are classified in L - Antineoplastic and immunomodulating agents.

The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability. The DDDs of depot preparations are calculated as the dose divided by the dosing interval.


G03H ANTIANDROGENS

G03HA Antiandrogens, plain

Finasteride used for treatment of benign prostatic hypertrophy is classified in G04CB.

The DDDs are based on the treatment of hypersexualism.

G03HB Antiandrogens and estrogens

This group comprises all combinations of cyproterone and estrogen regardless of indication.

The DDDs are based on the treatment of hirsutism or prophylaxis of postmenopausal osteoporosis.

Last updated: 2024-01-26